Fepod
Private Company
Funding information not available
Overview
Fepod is a privately-held, pre-revenue diagnostics company founded in 2017 and based in Helsinki, Finland, with a mission to transform acute care diagnostics. Its core innovation is a portable, fingerprick-based electrochemical platform that aims to provide lab-quality results at the patient's side within minutes, enabling faster clinical decisions. Backed by lead investor Almaral Oy and accepted into the Mayo Clinic Innovation Exchange, Fepod is advancing its first paracetamol test through clinical validation and regulatory steps, targeting a global leadership position in acute care POC diagnostics by 2030.
Technology Platform
Portable, fingerprick-based electrochemical diagnostics platform integrating disposable test strips, a pocket-sized reader, and a mobile phone with cloud-based data analysis.
Opportunities
Risk Factors
Competitive Landscape
Fepod competes in the point-of-care toxicology and acute care diagnostics market against large, diversified players like Abbott (i-STAT), Roche (cobas), and Siemens, as well as specialized toxicology test providers. Its key differentiators are the combination of true portability (pocket-sized), fingerprick sampling, and a claimed lab-grade quantitative result in minutes, targeting a gap between qualitative POC tests and slower central lab assays.